# A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

> **NCT04694560** · — · WITHDRAWN · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- CLL
- SLL
- CLL/SLL
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **OTHER:** Treatment Free Observation

## Key facts

- **NCT ID:** NCT04694560
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-12-22
- **Primary completion:** 2023-03-06
- **Final completion:** 2023-03-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of potential participants given the other treatment options currently available to people
- **Last updated:** 2025-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04694560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04694560, "A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04694560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*